Madrigal Pharmaceuticals, Inc.
Financials
Valuation Metrics
Madrigal Pharmaceuticals, Inc.'s Market Cap is $9.92B. At end of 2025 it was $13.06B. Ranked #879 of 3,114 in US market (top 28%), #273 of 1,469 on NASDAQ (top 19%), #43 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.92B | US#879/3,114 Sec#43/265 |
| Revenue | $1.28B | US#1,723/3,114 Sec#45/265 |
| Net Income | $-325M | US—/3,114 Sec—/265 |
| Total Assets | $1.24B | US#2,362/3,114 Sec#79/265 |
| Net Assets | $524M | US#2,200/3,114 Sec#105/265 |
| Employees | 915 | US#2,015/3,114 Sec#56/265 |
| Value | ||
| P/B | 18.94x | US#2,785/3,114 Sec#220/265 |
| P/S | 7.73x | US#2,624/3,114 Sec#106/265 |
| FCF Yield | -2.08% | US—/3,114 Sec—/265 |
| Profitability | ||
| ROE | -62.07% | US#2,720/3,114 Sec#178/265 |
| ROA | -26.12% | US#2,857/3,114 Sec#149/265 |
| Op. Margin | -25.13% | US#2,598/3,114 Sec#103/265 |
| Revenue Growth | 149.04% | US#67/3,114 Sec#24/265 |
| Financial Health | ||
| Debt Ratio | 137.65% | US#1,403/3,114 Sec#181/265 |
| Total Debt | $348M | US#2,048/3,114 Sec#74/265 |
| FCF | $-206M | US#2,789/3,114 Sec#211/265 |
| Cash | $293M | US#1,435/3,114 Sec#81/265 |
| Current Ratio | 3.20x | US#724/3,114 Sec#181/265 |
| Performance | ||
| 1Y Return | 0.65% | US#1,483/3,114 Sec#136/265 |
| 1M Return | -14.61% | US#2,447/3,114 Sec#162/265 |
| From 52W High | -30.03% | US#1,791/3,114 Sec#103/265 |
| 1Y MDD | -29.36% | US#1,251/3,114 Sec#63/265 |
| Trading | ||
| Volume | 211,608 shares | US#2,624/3,114 Sec#250/265 |
| Trading Value | $91M | US#948/3,114 Sec#51/265 |
| Per Share | ||
| EPS | $-14.10 | US—/3,114 Sec—/265 |
| BPS | $22.72 | US#1,120/3,114 Sec#23/265 |
Company Info
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.